In this closing segment, Drs. Lovly and Shaw synthesize the most important lessons from the 7-year CROWN update, address the study's remaining limitations and unanswered questions, and reflect on what this data means for the broader landscape of ALK-positive NSCLC care — from treatment guidelines to payer decision-making to patient survivorship.
Built from the experiences of patients, advocates and clinicians, a new MASH patient journey map offers a roadmap for navigating diagnosis and highlights the need for greater public understanding of the disease.
Financial sustainability and innovation are interdependent, as clinician-led contracting strategies that improve outcomes generate savings that fund further innovation.
This segment brings together two essential threads — the broader context of lorlatinib's remarkable durability relative to earlier ALK inhibitors, and the practical, multidisciplinary strategies clinicians need to support patients on long-term therapy — while making a compelling case for why these data are directly relevant to community oncology practice.
This segment addresses one of the most practically important aspects of lorlatinib therapy — its distinct and manageable safety profile — and provides clinicians with actionable guidance on dose optimization strategies to support long-term treatment tolerability.
Lung cancer has shifted from a rare, smoking-driven disease to one increasingly seen in young non-smokers, especially women, with possible links to pesticide exposure from otherwise “healthy” diets.
Aksharananda (Akshar) Rambachan, M.D., an UCSF physician-researcher, says that when used together, the numeric pain score and function scores give clinicians a far more complete clinical picture of a patient’s pain.
Thomas Martens, M.D., explains what drives adoption and how CONNECT's Level A evidence could move CGM coverage.
This segment introduces the Phase III CROWN study, providing essential background on its design and framing the remarkable significance of reporting 7-year follow-up data in the setting of advanced, stage 4 ALK-positive NSCLC.
